<DOC>
	<DOCNO>NCT02042482</DOCNO>
	<brief_summary>The purpose study determine whether combination Q10 , L-carnitine multivitamin mineral complex effective treatment patient low intermidiate1-2 risk Myelodysplastic syndrome</brief_summary>
	<brief_title>The Effect Combination Ultra Q10 L-carnitine Course Myelodysplastic Syndrome</brief_title>
	<detailed_description>The primary objective study assess response ( measured increase blood count , cytogenetic/molecular change bone marrow , improve endurance ) supplement treatment . The secondary objective determine : Quality life assessment ( FACT : QOL Questionnaire ) Cancer fatigue reduction . Physiological functioning assessment Rate depth transfusion reduction Duration response . Time progression . Overall survival . Estimated cytokine profile another immunological biochemical parameter mitochondrial function six month treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Patient willing able complies protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part standard medical care ; understanding consent may withdraw patient time without prejudice future medical care . Patient old 18 year time signing informed consent . Patients older 80 year sign inform consent psychogeriatric evaluation . Patient diagnose Myelodysplastic syndrome , Low risk intermediate1risk accord international prognostic scoring system hemoglobin level le 11g/l platelet less 100000/ mcl absolute neutrophil count less 1000/mcl . With without fatigue syndrome . INT2 high risk patient may include trial eligible treatment except Best Supportive Cure failure conventional treatment approach . Bone marrow aspiration examination include cytogenetics perform 12 month inclusion absence cliniclaboratory evidence progressive disease last month Patient lifeexpectancy &gt; 3 month Any serious medical condition , include presence laboratory abnormality , place subject unacceptable risk participates study confounds experimental ability interpret data study . Pregnant lactate female . Prior history malignancy , MDS , unless subject free disease â‰¥ 3 year . Exceptions include follow : Basal cell carcinoma skin , Squamous cell carcinoma skin , Carcinoma situ cervix , Carcinoma situ breast , Incidental histological finding prostate cancer ( TNM stage T1a T1b ) . Bone marrow blast count &gt; 30 % . Patient know active infectious hepatitis B C , HIV infection Administration investigational drug last 3 month . High risk MDS patient INT2 patient candidate cytoreductive epigenetics treatment . Any psychological , sociological condutions likely affect compliance study followup schedule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Ultra coenzyme Q10</keyword>
	<keyword>L-carnitine</keyword>
</DOC>